Body Weight
Methodology & AI Transparency ⓘ
Body Weight Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is body weight? Body weight is the total mass of your body.
- 2 Real-world patient consensus: Federal ICD-10-CM code R63.4 categorizes Body Weight under Weight Management & Metabolic Syndrome.
- 3 Typical cash cost range: Workup highlights for Body Weight (R63.4): incretin therapy candidacy in Body Weight (R63.4: review).
- 4 Top reported side effects / signs: Key Weight & Metabolism biomarkers for Body Weight (R63.4): Waist-to-Height Ratio [Body Weight R63.4] & HOMA-IR Insulin Resistance in Body Weight (R63.4: Index) (< 1.4 (R63.4)).
Ask our AI Specialists anything about Body Weight
What Is Body Weight?
What is body weight? Body weight is the total mass of your body. Keeping track of your weight is one way to check for changes in your health, but it can't tell you the whole story. That's because your weight includes muscle, bone, fat, and water. Also, everyday factors can play a role in your weight, such as your: Diet Activity level Stress level Sleep habits Family history and genetics Age What factors help determine a healthy body weight? A healthy weight is more than just a number on the scale. It's about feeling good, having energy, and lowering your risk of disease. Your health care provider can help you determine a healthy body weight based on several factors.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Body Weight (R63.4, Weight & Metabolism) reflects blunted endogenous GLP-1/PYY in Body Weight (R63.4: satiety hormone release). Cross-referenced with NIH MeSH (Body Weight Changes, Body Weight), longitudinal control is benchmarked via Waist-to-Height Ratio [Body Weight R63.4].
Common Symptoms & Clinical Signs
- • Family history and genetics
- • Underweight. Your weight is lower than it should be for your health
- • Presentation of Body Weight (R63.4): joint load discomfort in Body Weight (R63.4: in knees, hips,)
- • Secondary Body Weight clinical sign: daytime sluggishness or in Body Weight (R63.4: loud snoring linked)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Body Weight Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | R63.4 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Weight Management & Metabolic Syndrome | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Waist-to-Height Ratio [Body Weight R63.4] | < 0.50 (R63.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HOMA-IR Insulin Resistance in Body Weight (R63.4: Index) | < 1.4 (R63.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ALT & Fasting in Body Weight (R63.4: Triglycerides) | ALT < 25 U/L; TG < 100 mg/dL (R63.4) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Body Weight
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Phentermine Hydrochloride Lomaira, Phentermine HCl • RxCUI 803353 | Sympathomimetic Amine Anorectic | 89% | $0.0848 | $ 11.93 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Body Weight)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Potent incretin-based therapy for: What a 5,140-Participant Study Found The side effects related to semaglutide and tirzepatide were primarily of mild-to-moderate severity and mostly gastrointestinal, which was more frequent during the dose-titration period and leveled off during the treatment period. Obesity reviews : an official journal of the International Association for the Study of Obesity • 2024-05-15 • Meta-Analysis | N = 5,140 | 99/100 | PMID 38463003 ↗ |
| New Insights on Tirzepatide as a novel effective and safe strategy for treating: What a 11,758-Participant Study Found Tirzepatide, as a weight loss drug, significantly reduces BMI, waist circumference and body weight while gastrointestinal adverse reactions need to be vigilant. Frontiers in public health • 2024-01-15 • Meta-Analysis | N = 11,758 | 99/100 | PMID 38356942 ↗ |
| New Insights on Evaluation and comparison of real-world benefits and safety of tirzepatide and: What a 34,166-Participant Study Found Both Tir and Sem demonstrated favorable antidiabetic effects and were particularly suitable for T2DM patients who were obese or overweight. Pharmacological research • 2024-01-15 • Meta-Analysis | N = 34,166 | 99/100 | PMID 38061595 ↗ |
| New Insights on Benefits and safety of ipragliflozin as add-on to metformin for type 2: What a 847-Participant Study Found Results : Five RCTs with 847 patients were included. Postgraduate medicine • 2019-11-15 • Meta-Analysis | N = 847 | 97/100 | PMID 31414934 ↗ |
| New Insights on Glucagon-like peptide-1 receptor agonists for weight management in mental: What a 595-Participant Study Found S-SEM(QW) may be the preferred treatment option, given its largest estimated effects versus control on body weight; however, its comparative ranking is uncertain due to sparse networks, substantial. Translational psychiatry • 2026-07-08 • Meta-Analysis | N = 595 | 97/100 | PMID 42420255 ↗ |
Body Weight Patient Community & “People Like Me” Threads
Filter Body Weight community threads and patient logs by age, biological sex, dosage, and treatment duration.